US 12,448,415 B2
Compositions and methods for inhibition of alphavirus infection
Michael Diamond, St. Louis, MO (US); Daved Fremont, St. Louis, MO (US); Rong Zhang, St. Louis, MO (US); Arthur Kim, St. Louis, MO (US); Larissa Thackray, St. Louis, MO (US); Katherine Basore, St. Louis, MO (US); and Christopher A. Nelson, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Appl. No. 16/959,867
Filed by Washington University, St. Louis, MO (US)
PCT Filed Jan. 4, 2019, PCT No. PCT/US2019/012435
§ 371(c)(1), (2) Date Jul. 2, 2020,
PCT Pub. No. WO2019/136316, PCT Pub. Date Jul. 11, 2019.
Claims priority of provisional application 62/672,080, filed on May 16, 2018.
Claims priority of provisional application 62/671,680, filed on May 15, 2018.
Claims priority of provisional application 62/613,658, filed on Jan. 4, 2018.
Prior Publication US 2020/0407401 A1, Dec. 31, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 38/46 (2006.01); A61K 45/06 (2006.01); C07K 16/08 (2006.01); C12N 15/113 (2010.01)
CPC C07K 14/005 (2013.01) [A61K 38/465 (2013.01); C07K 16/08 (2013.01); C12N 15/113 (2013.01); A61K 45/06 (2013.01); C07K 2319/02 (2013.01); C07K 2319/30 (2013.01); C07K 2319/50 (2013.01); C12N 2310/20 (2017.05); C12Y 301/00 (2013.01)] 20 Claims
 
1. A fusion protein comprising:
an Mxra8 region; and
an Fc region downstream from the Mxra8 region;
wherein:
the Mxra8 region comprises one of a mouse Mxra8 extracellular domain and a human Mxra8 extracellular domain;
the Fc region comprises one of mouse IgG2b, human IgG1, and human IgG1 with N297Q mutation; and
the fusion protein reduces inflammation and infection by an arthritogenic alphavirus.